<DOC>
	<DOCNO>NCT02749331</DOCNO>
	<brief_summary>An open-labelled , uncontrolled , single-center Phase I/IIa clinical study evaluate safety repeat infusion AdVince hepatic artery patient metastatic neuroendocrine tumor ( NETs ) , possible determination maximum tolerate dose .</brief_summary>
	<brief_title>Study Recombinant Adenovirus AdVince Patients With Neuroendocrine Tumors ; Safety Efficacy</brief_title>
	<detailed_description>An open-labelled , uncontrolled , single-center Phase I/IIa clinical study evaluate safety repeat infusion AdVince hepatic artery patient metastatic neuroendocrine tumor ( NETs ) , possible determination maximum tolerate dose . Secondary objective include evaluate anti-tumoral efficacy AdVince infusion metastatic neuroendocrine tumor , determine replication profile AdVince determine humoral ( antibody ) cytokine-mediated immune response AdVince . Minimum 12 maximum 35 patient include , number base toxicity observe .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>1 . SubjectÂ´s write informed consent 2 . Histologically radiologically confirm progressive neuroendocrine carcinoma gastrointestinal , pancreatic bronchial origin multiple liver metastasis . Progression Clinical symptom tumor growth verify last 6 month CT MRI 3 . Cancer consider resectable potential cure tumor reduction 4 . Patent portal vein adequate liver perfusion 5 . Liver dominant disease involvement &lt; 60 % liver parenchyma 6 . Karnofsky performance status &gt; =70 % 7 . Life expectancy &gt; =6 month 8 . &gt; =18 year age 9 . Must use reliable method contraception sexually active reproductive potential 10 . Plasma creatinine &lt; 105 ug/ml 11 . Aspartate transaminase ( AST ) , Alanine transaminase ( ALT ) Alkaline Phosphatase ( ALP ) &lt; 3.0fold upper limit normal 12 . Total bilirubin &lt; 2.0fold upper limit normal 13 . Prothrombin time ( PT ) /International Normalized Ratio ( INR ) &lt; 2.0 Prothromboplastin time ( PTT ) within normal limit 14 . Neutrophils &gt; 1500/ml , hemoglobin &gt; 100 g/L , platelet &gt; 100 000/ml 15 . Patients function NET cover somatostatin analog 1 . Known chronic liver dysfunction Before development metastatic cancer ( e.g . cirrhosis , chronic hepatitis ) 2 . Active infection , include document HIV hepatitis C 3 . Any viral syndrome diagnose within previous 2 week 4 . Chemotherapy within previous 4 week Before first treatment 5 . Radiotherapy target tumor site within last 24 week baseline CT scan 6 . Concomitant malignancy 7 . Pregnant lactating female 8 . Prior participation research protocol involve administration adenovirus vector 9 . Treatment investigational therapy within last 4 week , organ transplantation prior treatment , severe cardiovascular , metabolic pulmonary disease 10 . Continuing treatment cancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>